An Overview of Pegylated Filgrastim and Clinical Significance

Dipak Kumar Singha [1*], Pratik Garai [1], Suman Santra [1], Aftab Amed [1], Arindam Chakraborty [2]

[1] Department of Pharmaceutical Biotechnology, Calcutta Institute of Pharmaceutical Technology and Allied Health Sciences, Banitabla, Uluberia, Howrah, West Bengal, India - 711316.

[1*] Department of Pharmaceutical Biotechnology, Calcutta Institute of Pharmaceutical Technology and Allied Health Sciences, Banitabla, Uluberia, Howrah, West Bengal, India - 711316.

[2] Department of Pharmaceutical Biotechnology, School of Pharmacy, Seacom Skills University, Bolpur, West Bengal - 731236

*Author for Correspondence: dsinghacipt@gmail.com

Abstract

In medication discovery, pegylation the covalent attachment of polyethylene glycol (PEG) chains to biomolecules including proteins, peptides, or nucleic acids—has emerged as a key tactic. This alteration improves the therapeutic medicines' pharmacokinetic and pharmacodynamic characteristics, providing increased bloodstream solubility, stability, and half-life. Additionally, pegylation lessens enzymatic breakdown, inhibits immunogenicity, and delays the immune system's quick clearance. Gene delivery systems, vaccinations, and therapeutic proteins have all been developed using this method. The review looks at the difficulties in optimizing pegylation, including the possibility of changing the drug's biological action and the variation in PEG chain length. The study also covers the successful clinical uses of pegylated medications, including PEGylated interferons, liposomes, and enzymes, emphasizing how well they work as therapeutics to treat diseases like cancer, viral infections, and genetic disorders. It ends by examining new developments and pegylation's promise to improve drug delivery and personalized treatment in the future.

Keywords: Pegylation, Polyethylene glycol (PEG), Immunogenicity, Liposomes, Enzymes.

INTRODUCTION

Pegylation, the covalent attachment of polyethylene glycol (PEG) chains to therapeutic molecules such as proteins, peptides, and nucleic acids, has emerged as a transformative technology in the field of drug development. The process of modifying biomolecules with PEG has garnered significant attention due to its ability to enhance the pharmacokinetic and pharmacodynamic properties of these agents, leading to improved therapeutic efficacy, reduced

toxicity, and enhanced patient compliance. The innovation of pegylation has been instrumental in overcoming several challenges inherent in biologic drug development, such as poor solubility, rapid renal clearance, immunogenicity, and susceptibility to proteolytic degradation [1].

The advantages of pegylation go far beyond pharmacokinetics; this alteration may affect the drug's immunogenicity, bioavailability, and tissue distribution, among other properties. The addition of PEG chains makes the altered molecule more sterically protected and hydrophilic, preventing the immune system from clearing it quickly and shielding it from enzymatic degradation [2,3].

PEGylated liposomal formulations have improved the delivery of chemotherapeutic agents, increasing their efficacy and decreasing side effects, while PEGylated interferons, for instance, have demonstrated improved patient compliance in the treatment of hepatitis C by lowering the frequency of injections needed.

The need for safe and effective drug delivery methods has increased recently due to the introduction of biologic therapies and targeted treatments for a number of illnesses, such as cancer, genetic disorders, and viral infections. By increasing their circulation duration and reducing their immunogenicity, PEGylated monoclonal antibodies have transformed the therapy of autoimmune disorders and cancer. Similarly, for gene therapy applications, PEGylated gene delivery methods have demonstrated potential in enhancing the therapeutic transport of nucleic acids, including DNA and RNA [4].

Some patients have developed anti-PEG antibodies, which could compromise the efficacy of PEGylated medications by causing hypersensitivity reactions or counteracting their therapeutic effects. Concerns have been raised by this problem about the use of PEGylated medications in some patient groups, especially those who need ongoing care. Thus, research is being done to better understand how the immune system reacts to PEGylated molecules and to create plans to lessen any negative consequences that might be associated to the immune system [5,6].

The goal of this extensive analysis is to present a complete investigation of pegylation technology, emphasizing its mechanics, conjugation techniques, benefits, and drawbacks. With an emphasis on therapeutic proteins, liposomes, enzymes, and gene delivery systems, it will explore the numerous uses of pegylation in drug development [7]. The review's analysis of pegylation technology's present status will shed light on its potential to further targeted treatment approaches and biologic drug development in the future [8].

In summury, pegylation has emerged as a crucial technique in the creation of medicinal and biologic compounds.. Pegylation is positioned to be a key component of the upcoming generation of targeted therapeutics, providing better drug delivery methods and more potent treatments for patients globally as research in this area progresses [9].

Chemistry behind Pegylation

To change a molecule's physicochemical characteristics, polyethylene glycol (PEG) chains can covalently connect to proteins, peptides, lipids, or nucleic acids. This process is known as pegylation. The synthetic polymer PEG is made up of repeated units of ethylene glycol (-CH_2–CH_2–O–). Its molecular weight can vary, with common versions ranging from 1 kDa to more than 40 kDa. The conjugated biomolecule's solubility, stability, and pharmacokinetic characteristics can be significantly changed by the hydrophilic and flexible polymer chain that is introduced during the pegylation process [10].

PEG Conjugation Mechanisms

- **Direct Conjugation:** Attaching PEG molecules directly to functional groups on the target molecule is known as "direct pegylation." Amino groups (-NH_2), carboxyl groups (-COOH), thiol groups (-SH), or hydroxyl groups (-OH) are the functional groups that are most frequently targeted for pegylation. Usually, these groups are present on the surface of medicinal substances or in the amino acids of proteins [11].
- **Amine (–NH_2) Group Conjugation:** Conjugating PEG to primary amine groups via an amide bond is the most widely utilized method. PEG derivatives with reactive groups, like isothiocyanate or succinimidyl ester (NHS-ester), are frequently utilized to create strong amide bonds with proteins or peptides. The NHS group is released as a byproduct of the reaction between the NHS-ester and the free amino group, which forms a covalent bond [12].
- **Carboxyl (–COOH) Group Conjugation:** Carbodiimide reagents, such as EDC or EDC/NHS, can help carboxyl groups react with amines by forming amide bonds. PEG is commonly coupled to proteins or other compounds with free carboxyl groups via this technique [13].

1. **Linker-Based Conjugation:** In order to offer flexibility, stability, and occasionally certain cleavage qualities, linker-based pegylation uses a chemical spacer, also known as a linker, between PEG and the biomolecule. The linkers can be made to break down under particular chemical or enzymatic circumstances, enabling the biomolecule to be released in a controlled manner [14].
2. **The most common linkers are:**
    - **Disulfide Linkers:** PEG and the molecule are joined by a disulfide bond (–S–S–) in these linkers. These bonds can be used for targeted medication administration since they break down in the intracellular space's reducing environment [15].
    - **Peptide Linkers:** PEG can be attached to the biomolecule using a peptide sequence that can be broken down by particular enzymes, such as proteases or matrix metalloproteinases. The pegylated agent can be released at the target site under regulated conditions thanks to this method [16].
    - **Hydrazone Linkers:** These linkers, which are made up of hydrazine and ketone/aldehyde groups, can cleave in acidic environments but remain stable at neutral pH levels [17].

Techniques Behind Pegylation

Pegylation is the technique of covalently attaching polyethylene glycol (PEG) chains to molecules, such as proteins, peptides, nucleic acids, or liposomes, in order to improve their stability, pharmacokinetic characteristics, and immunogenicity. The three main methods of pegylation are-

1. Direct Conjugation: PEG chains connect directly to functional groups on the target molecule, such as amino, carboxyl, thiol, or hydroxyl groups, in a process known as direct conjugation. The most used method for pegylating peptides and proteins is this one [18].

- **Amine-based Conjugation:** This technique uses PEG derivatives with reactive groups, such as succinimidyl esters (NHS-ester), to conjugate PEG to primary amines ($-NH_2$) on the target molecule. A stable amide bond is created when these reactive PEG derivatives interact with the amine group. The NHS group is released as a byproduct when the NHS-ester forms an intermediate that subsequently covalently binds to the amino group on the biomolecule [19].
- **Carboxyl-based Conjugation**: With this technique, carboxyl groups (-COOH) are activated to react with amines. To activate the carboxyl group and promote the creation of an amide bond between PEG and the target molecule, chemicals such as carbodiimides (such as EDC) are employed.
- **Thiol-based Conjugation**: PEG can be conjugated via a thiol-reactive group, such as maleimide or 5-ethylthio-1,2,3-diazabicyclo[5.4.0]undec-7-ene (EDC), when the target molecule has thiol groups (–SH). Stable thioether bonds are created when the maleimide groups on PEG interact with the free thiol groups on cysteine residues.
- **Hydroxyl-based Conjugation**: PEG can be covalently attached to hydroxyl groups (-OH), which are frequently present in specific proteins, lipids, or carbohydrates, by using PEG molecules with reactive groups like tosylate or epoxide. In contrast to amine-based conjugation, these reactions are used less frequently [20,21].

2. Linker-Based Conjugation: Linker-based pegylation adds flexibility, stability, or controlled release by using a chemical spacer or linker between PEG and the biomolecule.

- **Disulfide Linkers**: With these linkers, the PEG and the biomolecule are joined by a disulfide bond (-S-S-). Disulfide linkers are perfect for controlled release, especially in intracellular drug delivery systems, because they cleave in the reducing environment of cells or tissues. The medicinal chemical is released more precisely when the disulfide link is broken.
- **Peptide Linkers**: This method makes use of a brief peptide sequence that certain proteases can cleave. For instance, peptide linkers can be broken down by enzymes like matrix metalloproteinases (MMPs) or specific esterases, allowing the pegylated medication to be released at the site of action in a regulated way. This is

especially helpful when targeting tissues or cells with overexpressed proteases, such as cancer cells.

- **Hydrazone Linkers**: A hydrazine group combines with carbonyl groups (–C=O), usually aldehydes or ketones, to produce hydrazone linkers between PEG and the target molecule. This method is helpful for targeted distribution to acidic tumor microenvironments or lysosomes because hydrazone bonds are stable at neutral pH but can cleave in acidic conditions [22,23].

3. Enzymatic or Site-Specific Pegylation: The attachment of PEG to specified locations on the target molecule is catalyzed by specialized enzymes in enzymatic pegylation procedures.

- **Transglutaminase-Mediated Pegylation**: The creation of covalent connections between amine and glutamine residues is catalyzed by the enzyme transglutaminase. Transglutaminase can help PEG covalently connect to proteins at particular locations by adding PEG groups that include reactive groups like isocyanate [24].
- **Sortase-Mediated Pegylation**: Sortase is an enzyme that facilitates the transpeptidation reaction, which is the process by which peptides or proteins bind to other molecules. The enzyme helps PEG covalently conjugate to a target peptide or protein at a particular location in sortase-mediated pegylation. This method is useful for binding PEG to specific sites on a molecule without changing its biological function since it is very precise.
- **Click Chemistry:** A class of reactions known as "click chemistry" is frequently employed for site-specific pegylation because it is extremely effective, selective, and bioorthogonal. PEG can be highly selectively conjugated to proteins or peptides using this process, giving exact control over the attachment point [25,26].

4. Site-Specific Pegylation Using Genetic Engineering

Sometimes, in order to promote pegylation at exact sites, particular functional groups—like an azide or alkyne group—are introduced into the target molecule using genetic engineering techniques [27].

Pharmacokinetics Behind Pegylation

Pegylation primarily affects the pharmacokinetic parameters of absorption, distribution, metabolism, and elimination.

I. Absorption

The absorption of medications from the site of administration is not substantially impacted by pegylation per se. Pegylation, however, may affect the therapeutic molecule's solubility in injectable medications. Pegylation keeps medications that must be administered intravenously soluble in aqueous solutions by avoiding precipitation or aggregation, which could otherwise hinder absorption [28].

II. Distribution

The size and hydrophilicity of the PEG chains affect how pegylated medications are distributed. PEGylation makes the drug's molecules bigger, which may make it harder for it to pass through biological membranes [29]. Larger pegylated molecules are often only found in the circulation and extracellular fluid because they are less likely to move freely across cell membranes. The prolonged circulation duration of pegylation is one of its main pharmacokinetic advantages. Compared to their non-pegylated equivalents, PEGylated medications often have a longer half-life in the bloodstream. Pegylated molecules have a longer half-life due to this "stealth" effect, which lowers dosage frequency and increases patient compliance [30,31].

III. Metabolism

Pegylation increases a drug's stability by lowering its vulnerability to enzymatic breakdown. Because PEG chains function as a physical barrier, enzymes like proteases and esterases, which normally break down therapeutic proteins or peptides, have a harder time cleaving PEG-modified molecules. Additionally, the biomolecule's immunogenicity may be decreased by PEG modification, decreasing the likelihood that the immune system will target it for destruction. Because of this, pegylated medications frequently have slower metabolisms than their non-pegylated counterparts [32].

IV. Elimination

The larger size and hydrophilicity of pegylated medications have a major impact on their removal. When compared to molecules that are not pegylated, PEGylation usually lowers renal clearance, especially for proteins or peptides that the kidneys would normally clear quickly. Because pegylated molecules are bigger, they can't cross the kidneys' glomerular filtration barrier, which lowers renal excretion. The reticuloendothelial system (RES), which is primarily found in the liver and spleen and is where macrophages and other phagocytic cells remove foreign particles and molecules, is more likely to remove pegylated medications [33].

Extended Half-Life and Reduced Clearance: The prolonged half-life of the altered medication is a characteristic of pegylation. Pegylation serves to extend the circulation half-life of the molecule by decreasing the rate of clearance via the renal and RES routes. Pegylated interferons, for instance, have long half-lives when used to treat hepatitis C, which lowers injection frequency and increases patient compliance. Longer circulation durations are another feature of pegylated chemotherapeutic drugs, such as liposomal doxorubicin, which improves their therapeutic efficacy while lowering systemic toxicity [34].

5. Pharmacokinetic Models and Dosing Considerations

Numerous methods, such as compartmental models, population pharmacokinetics, and non-compartmental analysis, can be used to model the pharmacokinetic characteristics of pegylated medications [35]. These models consider variables such the PEG chain's size and structure, the kind of molecule being altered, and the administration method. Clinicians can tailor dosing schedules to balance efficacy and avoid negative effects by knowing the PK parameters of

pegylated medicines. For chronic illnesses that need long-term care, PEGylated medications with longer half-lives, for instance, can be dosed less frequently-once a week as opposed to daily [36].

Pharmacodynamics behind Pegylation

The pharmacodynamic characteristics of these medications are greatly influenced by pegylation, which is the covalent attachment of polyethylene glycol (PEG) chains to molecules like proteins, peptides, or other medicinal agents.

I. Enhanced Stability and Bioactivity

Pegylation's capacity to increase the therapeutic molecule's stability is one of its main pharmacodynamic benefits. The medication is protected by PEGylation, which reduces its vulnerability to oxidation, proteolytic degradation, and other types of chemical instability. This enhanced stability is crucial for biologics, such as proteins or peptides, since it helps sustain the drug's bioactivity over an extended duration, enabling it to continue serving its intended therapeutic purpose.

II. Reduction of Immunogenicity

The decrease in immunogenicity is a major pharmacological effect of pegylation. The immune system may identify a foreign protein or therapeutic substance as a possible pathogen upon administration, causing the creation of antibodies that have the ability to neutralize or render the medicine inactive. The drug molecule's surface is sterically protected by adding PEG chains, which lowers the possibility of an immunological response by preventing immune cells from recognizing it.

III. Extended Duration of Action

The prolonged duration of action of pegylated medications has a significant impact on their pharmacodynamics. Pegylated medicines have longer half-lives than their non-pegylated counterparts because pegylation slows down the pace at which a medication is removed from the body (by renal clearance and identification by the reticuloendothelial system). The length of the therapeutic impact is directly correlated with this half-life extension. Pegylated interferons [37].

IV. Alteration of Drug Receptor Binding

Pegylation may change the drug's receptor-binding characteristics, but it can also have major positive effects on immunogenicity and stability. A drug molecule's ability to attach to its receptor or target site may be sterically hampered by the addition of PEG chains. Extended half-life and decreased immunogenicity can be achieved while maintaining or even improving the drug's pharmacodynamic characteristics by carefully choosing the location and level of pegylation.

V. Targeted Delivery and Tissue Penetration

Pegylation may also affect how the medication is distributed throughout the body. Pegylated molecules are more difficult to diffuse into tissues or cross cell membranes due to their greater size. When targeting certain locations, such the bloodstream or specific organs, this size increase can be advantageous because it can lessen the drug's dispersion to off-target places. This can enhance the medication's therapeutic index and lessen adverse effects.

VI. Reduced Side Effects and Toxicity

Pegylation can also result in less side effects and toxicity because it decreases a drug's immunogenicity and changes its distribution to lessen off-target effects. Pegylated medications can produce therapeutic benefits at lower doses by delaying circulation and limiting fast clearance, which lowers the possibility of adverse responses. Additionally, the general safety profile of pegylated medications is enhanced by lowering nonspecific binding to healthy tissues [38].

Advantages Behind Pegylation

I. Increased Half-Life and Extended Duration of Action

The prolonged half-life of the changed molecule is one of the most important advantages of pegylation. The medication is less vulnerable to immunological detection and quick renal clearance when PEG chains are attached [39].

II. Enhanced Stability and Protection

By shielding therapeutic compounds from oxidation, aggregation, and proteolytic degradation, PEGylation increases their stability. Over time, the drug's bioactivity is preserved and enzymatic degradation is prevented by the protective "shield" that the PEG chains create around it.

III. Reduced Immunogenicity

Because the PEG chains prevent the immune system from recognizing the therapeutic molecule, PEGylation aids in lowering immunogenicity. This lessens the possibility that the body will produce antibodies against the medication, which could result in allergic responses and a faster rate of elimination [40].

IV. Improved Bioavailability

PEG's hydrophilic properties make weakly water-soluble medications more soluble, which can increase bioavailability. This is especially helpful for treatments based on proteins or peptides that could otherwise have solubility issues.

V. Reduced Toxicity and Side Effects

Pegylated medications typically exhibit lower levels of toxicity and adverse effects because of their longer half-life and less systemic exposure. More regulated medication release is made possible by the longer circulation period, which lowers the possibility of negative reactions at high concentrations [41].

Applications of Pegylation

I. Biologic Drugs (Proteins and Enzymes)

The alteration of therapeutic proteins and enzymes is among the most important uses of pegylation. These biologic molecules would otherwise have a brief half-life because of quick renal clearance or immune system detection, but pegylation extends that period.

II. Cancer Therapy

Pegylation is a technique used in cancer treatment to alter chemotherapeutic drugs and nanoparticles to enhance their ability to reach tumor cells. Pegylated medications, such as pegylated liposomal doxorubicin, can more successfully target malignant areas and evade quick clearance [42].

III. Gene and Nucleic Acid Delivery

PEGylated liposomes or nanoparticles can enhance the stability, bioavailability, and cellular uptake of DNA, RNA, or small interfering RNA (siRNA). Pegylation is used in gene therapy and nucleic acid delivery systems.

IV. Vaccines and Immunotherapies

Pegylation has been investigated in the creation of immunotherapies and vaccines. It can improve the therapeutic potential of vaccine components by extending their stability and release duration. To enhance the immune response and lessen negative side effects, pegylated immunotherapy drugs are also being researched [43]

Challenges of Pegylation

I. Loss of Biological Activity

The possible loss of the therapeutic molecule's biological function is one of the main problems with pegylation. PEG chains have the ability to sterically block the active areas of proteins or peptides, preventing them from interacting with biological pathways or target receptors.

II. Immunogenicity

Pegylation is not always totally successful, but it usually lowers immunogenicity by protecting the medication from the immune system. Anti-PEG antibodies may form in some situations where the immune system is still able to identify the PEGylated molecule. These antibodies have the potential to decrease a drug's effectiveness by hastening its excretion from the body.

III. Manufacturing Complexity

Pegylation is a complicated process that includes purification procedures, conjugation condition adjustment, and the production of PEG derivatives. Careful control over the PEG chains' length, structure, and attachment sites is necessary to produce pegylated products that are reliable and of excellent quality [44].

IV. Cost

Another issue is the price of pegylation. The cost of producing drugs can be greatly raised by the chemical modification process, the requirement for extremely pure reagents, and specialized equipment. The total economics of pegylated medicines may be impacted by these additional expenses, particularly for chronic illnesses that call for ongoing care.

V. Regulatory Hurdles

Because of the intricacy of their manufacturing and the requirement for extensive testing to guarantee safety, efficacy, and consistency, regulatory approval for pegylated medications can be difficult. Before approving pegylated medications, regulatory bodies need comprehensive information on their pharmacokinetics, pharmacodynamics, and immunogenicity [45]

Conclusion

Pegylation has been a game-changing technique in the creation of therapeutic agents, providing significant enhancements to the pharmacokinetic and pharmacodynamic characteristics of medications, especially biologics. Pegylation is a crucial technique in the treatment of a number of illnesses, including cancer, genetic disorders, and chronic conditions. It does this by attaching polyethylene glycol (PEG) chains to molecules such as proteins, peptides, and nanoparticles. This process improves stability, prolongs half-life, decreases immunogenicity, and increases bioavailability [46].

Pegylation is not without its difficulties, though. To guarantee the effective development and use of pegylated medications, potential problems such the loss of biological function, immunogenicity issues, manufacturing complexity, high prices, and regulatory obstacles must be properly managed. Notwithstanding these difficulties, pegylation's benefits make it a crucial tactic in the development of next-generation medications [47].

Disclaimer (Artificial intelligence)

It is hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.) and text-to-image generators have been used during the writing or editing of this manuscript.

Acknowledgement

The authors sincerely acknowledge the Calcutta Institute of Pharmaceutical Technology & AHS, Banitabla, Uluberia, Howrah, West Bengal, India-711316.

AUTHORS' CONTRIBUTIONS

Both the authors have same contribution to writing this article.

Reference:-

1. Li C, Li T, Tian X, An W, Wang Z, Han B, et al. Research progress on the PEGylation of therapeutic proteins and peptides (TPPs). Front Pharmacol [Internet]. 2024;15:1353626.
2. Talkington AM, McSweeney MD, Wessler T, Rath MK, Li Z, Zhang T, et al. A PBPK model recapitulates early kinetics of anti-PEG antibody-mediated clearance of PEG-liposomes. J Control Release [Internet]. 2022;343:518–27.
3. Shi D, Beasock D, Fessler A, Szebeni J, Ljubimova JY, Afonin KA, et al. To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives. Adv Drug Deliv Rev [Internet]. 2022;180(114079):114079.
4. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, et al. Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front Mol Biosci [Internet]. 2020;7:193.
5. Bhattacharya S, Prajapati BG, Singh S. A critical review on the dissemination of PH and stimuli-responsive polymeric nanoparticular systems to improve drug delivery in cancer therapy. Crit Rev Oncol Hematol [Internet]. 2023;185(103961):103961.
6. Cen J, Hou M, Liu S. Discrete polyethylene glycol derivatives as a potent impetus for next-generation biomedicines. Giant (Oxf) [Internet]. 2023;15(100169):100169.
7. Santhanakrishnan KR, Koilpillai J, Narayanasamy D. PEGylation in pharmaceutical development: Current status and emerging trends in macromolecular and immunotherapeutic drugs. Cureus [Internet]. 2024;16(8):e66669.
8. Hyldbakk A, Hansen T, Hak S, Borgos SEF. Polyethylene glycol (PEG) as a broad applicability marker for LC-MS/MS-based biodistribution analysis of nanomedicines. J Control Release [Internet]. 2024;366:611–20.
9. Turecek PL, Bossard MJ, Schoetens F, Ivens IA. PEGylation of biopharmaceuticals: A review of chemistry and nonclinical safety information of approved drugs. J Pharm Sci [Internet]. 2016;105(2):460–75.
10. Padín-González E, Lancaster P, Bottini M, Gasco P, Tran L, Fadeel B, et al. Understanding the role and impact of poly (ethylene glycol) (PEG) on nanoparticle formulation: Implications for COVID-19 vaccines. Front Bioeng Biotechnol [Internet]. 2022;10:882363.
11. Akbarzadehlaleh P, Mirzaei M, Mashahdi-Keshtiban M, Shamsasenjan K, Heydari H. PEGylated human serum albumin: Review of PEGylation, purification and characterization methods. Adv Pharm Bull [Internet]. 2016;6(3):309–17.
12. Patil US, Qu H, Caruntu D, O'Connor CJ, Sharma A, Cai Y, et al. Labeling primary amine groups in peptides and proteins with N-hydroxysuccinimidyl ester modified Fe3O4@SiO2 nanoparticles containing cleavable disulfide-bond linkers. Bioconjug Chem [Internet]. 2013;24(9):1562–9.
13. Mehata AK, Dehari D, Vikas, Priya V, Muthu MS. Drug-releasing textile materials: current developments and future perspectives. In: Fiber and Textile Engineering in Drug Delivery Systems. Elsevier; 2023. p. 1–38.
14. Eras A, Castillo D, Suárez M, Vispo NS, Albericio F, Rodriguez H. Chemical conjugation in drug delivery systems. Front Chem [Internet]. 2022;10:889083.

15. Ma W, Wang X, Zhang D, Mu X. Research progress of disulfide bond based tumor microenvironment targeted drug delivery system. Int J Nanomedicine [Internet]. 2024;19:7547–66.
16. Redondo-Gómez C, Parreira P, Martins MCL, Azevedo HS. Peptide-based self-assembled monolayers (SAMs): what peptides can do for SAMs and vice versa. Chem Soc Rev [Internet]. 2024;53(8):3714–73.
17. Yang X, Pan Z, Choudhury MR, Yuan Z, Anifowose A, Yu B, et al. Making smart drugs smarter: The importance of linker chemistry in targeted drug delivery. Med Res Rev [Internet]. 2020;40(6):2682–713.
18. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev [Internet]. 2016;99(Pt A):28–51.
19. Fernández M, Orozco J. Advances in functionalized photosensitive polymeric nanocarriers. Polymers (Basel) [Internet]. 2021;13(15):2464.
20. Hamley IW. PEG-peptide conjugates. Biomacromolecules [Internet]. 2014;15(5):1543–59.
21. Geoghegan KF. Modification of amino groups. Curr Protoc Protein Sci [Internet]. 2016;86(1):15.2.1-15.2.20.
22. Melnyk T, Đorđević S, Conejos-Sánchez I, Vicent MJ. Therapeutic potential of polypeptide-based conjugates: Rational design and analytical tools that can boost clinical translation. Adv Drug Deliv Rev [Internet]. 2020;160:136–69.
23. Zhao H, Yang K, Martinez A, Basu A, Chintala R, Liu H-C, et al. Linear and branched bicin linkers for releasable PEGylation of macromolecules: controlled release in vivo and in vitro from mono- and multi-PEGylated proteins. Bioconjug Chem [Internet]. 2006;17(2):341–51.
24. Sato H. Enzymatic procedure for site-specific pegylation of proteins. Adv Drug Deliv Rev [Internet]. 2002;54(4):487–504.
25. Dozier JK, Distefano MD. Site-specific PEGylation of therapeutic proteins. Int J Mol Sci [Internet]. 2015;16(10):25831–64.
26. Maullu C, Raimondo D, Caboi F, Giorgetti A, Sergi M, Valentini M, et al. Site-directed enzymatic PEGylation of the human granulocyte colony-stimulating factor: PEGylation of the G-CSF molecule by MTGase enzyme. FEBS J [Internet]. 2009;276(22):6741–50.
27. Belén LH, Rangel-Yagui C de O, Beltrán Lissabet JF, Effer B, Lee-Estevez M, Pessoa A, et al. From synthesis to characterization of site-selective PEGylated proteins. Front Pharmacol [Internet]. 2019;10:1450.
28. Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs [Internet]. 2008;22(5):315–29.
29. Shi L, Zhang J, Zhao M, Tang S, Cheng X, Zhang W, et al. Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery. Nanoscale [Internet]. 2021;13(24):10748–64.
30. Maurya P, Singh S, Saraf SA. Inhalable hybrid nanocarriers for respiratory disorders. In: Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems. Elsevier; 2020. p. 281–302.

31. Haynes MT, Huang L. Lipid-coated calcium phosphate nanoparticles for nonviral gene therapy. Adv Genet [Internet]. 2014;88:205–29.
32. da-Silva-Freitas D, Boldrini-França J, Arantes EC. PEGylation: a successful approach to improve the biopharmaceutical potential of snake venom thrombin-like serine protease. Protein Pept Lett [Internet]. 2015;22(12):1133–9.
33. Evans BJ, King AT, Katsifis A, Matesic L, Jamie JF. Methods to enhance the metabolic stability of peptide-based PET radiopharmaceuticals. Molecules [Internet]. 2020;25(10):2314.
34. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci [Internet]. 2008;97(10):4167–83.
35. Liu X, Ucakar B, Vanvarenberg K, Marbaix E, Vanbever R. Impact of administration route and PEGylation on alpha-1 antitrypsin augmentation therapy. J Control Release [Internet]. 2025;(113643):113643.
36. Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol [Internet]. 2013;2(4):e38.
37. Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics: A novel process for modifying pharmacokinetics. Clin Pharmacokinet [Internet]. 2001;40(7):539–51.
38. Santos JHPM, Torres-Obreque KM, Meneguetti GP, Amaro BP, Rangel-Yagui CO. Protein PEGylation for the design of biobetters: from reaction to purification processes. Braz J Pharm Sci [Internet]. 2018;54(spe).
39. Mishra P, Nayak B, Dey RK. PEGylation in anti-cancer therapy: An overview. Asian J Pharm Sci [Internet]. 2016;11(3):337–48.
40. Lee CS, Kulkarni Y, Pierre V, Maski M, Wanner C. Adverse impacts of PEGylated protein therapeutics: A targeted literature review. BioDrugs [Internet]. 2024;38(6):795–819.
41. Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, et al. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther [Internet]. 2022;7(1):48.
42. Grigoletto A, Mero A, Maso K, Pasut G. Transgultaminase-mediated nanoarmoring of enzymes by PEGylation. Methods Enzymol [Internet]. 2017;590:317–46.
43. Ginn C, Khalili H, Lever R, Brocchini S. PEGylation and its impact on the design of new protein-based medicines. Future Med Chem [Internet]. 2014;6(16):1829–46.
44. Zhang F, Liu M-R, Wan H-T. Discussion about several potential drawbacks of PEGylated therapeutic proteins. Biol Pharm Bull [Internet]. 2014;37(3):335–9.
45. Gundecha S, Shirolkar S, Deshkar S, Chitlange S, Shewale S, Jagtap RA. review on impact of pegylation on biopharmaceuticals. Int J Health Sci (IJHS) [Internet]. 2022;6622–34.
46. Gao Y, Joshi M, Zhao Z, Mitragotri S. PEGylated therapeutics in the clinic. Bioeng Transl Med [Internet]. 2024;9(1):e10600.
47. Bento C, Katz M, Santos MMM, Afonso CAM. Striving for uniformity: A review on advances and challenges to achieve uniform polyethylene glycol. Org Process Res Dev [Internet]. 2024;28(4):860–90.